{
  "risk_score_0_to_1": 0.85,
  "confidence_0_to_1": 0.95,
  "dominant_mechanisms": [
    {"mechanism": "mitochondrial_dysfunction", "score_0_to_1": 0.95},
    {"mechanism": "reactive_metabolite_formation", "score_0_to_1": 0.85},
    {"mechanism": "cholestasis_bsep_inhibition", "score_0_to_1": 0.1},
    {"mechanism": "immune_mediated_injury", "score_0_to_1": 0.2},
    {"mechanism": "oxidative_stress", "score_0_to_1": 0.8}
  ],
  "time_to_onset": "weeks_to_months",
  "dose_dependence": "idiosyncratic",
  "reversibility": "reversible_if_treated_early",
  "uncertainties": [
    "Inter-individual variability in mitochondrial DNA polymerase gamma (POLG) mutations",
    "Synergistic toxicity threshold with concomitant enzyme-inducing anticonvulsants"
  ],
  "citations": [
    "Silva, M. F., et al. (2008). Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review.",
    "Kassahun, K., et al. (1991). Metabolic activation of valproic acid to the reactive metabolite 4-ene-valproic acid."
  ]
}